Literature DB >> 21281977

Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies.

M Zouhair Atassi1, Behzod Z Dolimbek, Joseph Jankovic, Lance E Steward, K Roger Aoki.   

Abstract

This work was aimed at determining the BoNT/A L-chain antigenic regions recognized by blocking antibodies in human antisera from cervical dystonia patients who had become immunoresistant to BoNT/A treatment. Antisera from 28 immunoresistant patients were analyzed for binding to each of 32 overlapping synthetic peptides that spanned the entire L-chain. A mixture of the antisera showed that antibodies bound to three peptides, L11 (residues 141-159), L14 (183-201) and L18 (239-257). When mapped separately, the antibodies were bound only by a limited set of peptides. No peptide bound antibodies from all the patients and amounts of antibodies bound to a given peptide varied with the patient. Peptides L11, L14 and L18 were recognized predominantly. A small but significant number of patients had antibodies to peptides L27 (365-383) and L29 (379-397). Other peptides were recognized at very low and perhaps insignificant antibody levels by a minority (15% or less) of patients or had no detectable antibody with any of the sera. In the 3-dimensional structure, antibody-binding regions L11, L14 and L18 of the L-chain occupy surface areas and did not correlate with electrostatic potential, hydrophilicity/hydrophobicity, or temperature factor. These three antigenic regions reside in close proximity to the belt of the heavy chain. The regions L11 and L18 are accessible in both the free light chain and the holotoxin forms, while L14 appears to be less accessible in the holotoxin. Antibodies against these regions could prevent delivery of the L-chain into the neurons by inhibition of the translocation.
Copyright © 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21281977     DOI: 10.1016/j.imbio.2010.12.009

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  9 in total

1.  Enhancing toxin-based vaccines against botulism.

Authors:  Amanda Przedpelski; William H Tepp; Madison Zuverink; Eric A Johnson; Sabine Pellet; Joseph T Barbieri
Journal:  Vaccine       Date:  2018-01-04       Impact factor: 3.641

2.  Does Clostridium botulinum neurotoxin A exhibit molecular mimicry with thyroid autoantigens and cause thyroid complications in predisposed persons?

Authors:  M Zouhair Atassi; Philip R Deitiker
Journal:  Endocrine       Date:  2011-08       Impact factor: 3.633

Review 3.  Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis.

Authors:  Margherita Fabbri; Giorgio Leodori; Ricardo M Fernandes; Roongroj Bhidayasiri; Maria Jose Marti; Carlo Colosimo; Joaquim J Ferreira
Journal:  Neurotox Res       Date:  2016-01       Impact factor: 3.911

4.  Epitope mapping of botulinum neurotoxins light chains.

Authors:  Alexey Zdanovsky; Denis Zdanovsky; Maria Zdanovskaia
Journal:  Toxicon       Date:  2012-08-14       Impact factor: 3.033

Review 5.  Immunogenicity Associated with Botulinum Toxin Treatment.

Authors:  Steven Bellows; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2019-08-26       Impact factor: 4.546

Review 6.  Immunogenicity of botulinum toxins.

Authors:  Markus Naumann; Lee Ming Boo; Alan H Ackerman; Conor J Gallagher
Journal:  J Neural Transm (Vienna)       Date:  2012-09-25       Impact factor: 3.575

7.  Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin.

Authors:  B Vijayalakshmi Ayyar; Rajeev B Tajhya; Christine Beeton; M Zouhair Atassi
Journal:  Sci Rep       Date:  2015-10-28       Impact factor: 4.379

8.  Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature.

Authors:  Sara Samadzadeh; Beyza Ürer; Raphaela Brauns; Dietmar Rosenthal; John-Ih Lee; Philipp Albrecht; Harald Hefter
Journal:  Toxins (Basel)       Date:  2020-08-04       Impact factor: 4.546

9.  Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.

Authors:  Harald Hefter; Beyza Ürer; Raphaela Brauns; Dietmar Rosenthal; Sven G Meuth; John-Ih Lee; Philipp Albrecht; Sara Samadzadeh
Journal:  Toxins (Basel)       Date:  2022-01-06       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.